Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen's Aduhelm

Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen's Aduhelm

Source: 
Fierce Biotech
snippet: 

Eli Lilly is so serious about becoming the leader in Alzheimer’s disease with donanemab that, last year, the Indianapolis Big Pharma challenged competitor Biogen by launching a head-to-head trial comparing their two therapies.

So what gives the company the confidence? Lilly CEO David Ricks knows it’ll win.